Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes:current strategies and future perspectives

• 来源期刊: 药学学报（英文版）
• 关键词: Anticancer agents Antioxidants Direct conjugation Mitochondria-targeting Sensing agents
• 年，卷（期）: 2018,（6）
• 页码范围: 862-880
• 页数: 19页
• 语种: 英文

摘要

Mitochondrial targeting is a promising approach for solving current issues in clinical application of chemotherapy and diagnosis of several disorders.Here,we discuss direct conjugation of mitochondrial-targeting moieties to anticancer drugs,antioxidants and sensor molecules.Among them,the most widely applied mitochondrial targeting moiety is triphenylphosphonium (TPP),which is a delocalized cationic lipid that readily accumulates and penetrates through the mitochondrial membrane due to the highly negative mitochondrial membrane potential.Other moieties,including short peptides,dequalinium,guanidine,rhodamine,and F16,are also known to be promising mitochondrial targeting agents.Direct conjugation of mitochondrial targeting moieties to anticancer drugs,antioxidants and sensors results in increased cytotoxicity,anti-oxidizing activity and sensing activity,respectively,compared with their non-targeting counterparts,especially in drug-resistant cells.Although many mitochondria-targeted anticancer drug conjugates have been investigated in vitro and in vivo,further clinical studies are still needed.On the other hand,several mitochondria-targeting antioxidants have been analyzed in clinical phases Ⅰ,Ⅱ and Ⅲ trials,and one conjugate has been approved for treating eye disease in Russia.There are numerous ongoing studies of mitochondria-targeted sensors.